Sign inJoin waitlistJoin the waitlist

Bunja Rungruang

Program Director, Gynecologic Oncology Fellowship · Medical College of Georgia

Credentials: · · · · · ·

History

Gynecologic Oncology Fellowship · Medical College of Georgia
Present
Fellowship & Division Fellowship · Medical College of Georgia
Present
Medical College of Georgia
Present

Gynecologic Oncology
UPMC Medical Education
2011–2014
Obstetrics and Gynecology
UPMC Medical Education
2007–2011
University of Alabama at Birmingham
University of Alabama at Birmingham School of Medicine
2001–2005

Research

Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182
Journal of Clinical Oncology · 2015 · 201 citations
Multiplex glycan bead array for high throughput and high content analyses of glycan binding proteins
Nature Communications · 2018 · 69 citations
Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group…
Gynecologic Oncology · 2013 · 57 citations

David Mysona
13 papers · 12 as a resident
Sharad Ghamande
13 papers
SR
Scott Richard
9 papers · 3 as a fellow
Thomas Krivak
9 papers
Robert Higgins
8 papers
Bogna Brzezinska
7 papers · 7 as a fellow
Chad Hamilton
7 papers
Marian Johnson
7 papers · 7 as a fellow
Michael Bookman
7 papers
Neil Horowitz
7 papers
NR
Noah Rodriguez
7 papers
GM
George Maxwell
6 papers

Clinical trials

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2022–2032